Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | HPGD | P15428 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.72 |
| ▸ | USP2 | O75604 | 2/20 | 0.62 |
| ▸ | CASP1 | P29466 | 2/20 | 0.62 |
| ▸ | CASP7 | P55210 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | PNP | P00491 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9300858 | 0.82 | KDM4E (0.72) | ALDH1A1KDM4EKMT2AHPGDMEN1 | |
| SCHEMBL9303416 | 0.80 | KDM4E (0.72) | ALDH1A1KDM4EKMT2AHPGDMEN1 | |
| SCHEMBL1945491 | 0.80 | KDM4E (0.66) | ALDH1A1KDM4EKMT2AHPGDMEN1 | |
| SCHEMBL6093649 | 0.78 | KDM4E (0.80) | ALDH1A1KDM4EKMT2AHPGDMEN1 | |
| SCHEMBL6348563 | 0.77 | ALDH1A1 (0.62) | ALDH1A1KDM4EKMT2AHPGDMEN1 | |
| SCHEMBL14205210 | 0.75 | KDM4E (0.68) | ALDH1A1KDM4EKMT2AHPGDMEN1 | |
| SCHEMBL1946617 | 0.75 | HPGD (0.59) | ALDH1A1KDM4EKMT2AHPGDMEN1 | |
| SCHEMBL22111515 | 0.74 | KDM4E (0.78) | ALDH1A1KDM4EKMT2AHPGDMEN1 | |
| SCHEMBL5416955 | 0.74 | KDM4E (0.58) | ALDH1A1KDM4EKMT2AHPGDMEN1 | |
| SCHEMBL7673685 | 0.72 | MEN1 (0.56) | ALDH1A1KDM4EKMT2AHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1171442-B1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALLING INHIBITORS | CELL THERAPEUTICS INC (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6878715-B1 | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same | CELL THERAPEUTICS, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20050049262-A1 | Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same | CELL THERAPEUTICS, INC. (US) | 2005-03-03 | — | — | US | disclosed |
| US-20050032748-A1 | Substituted 2,5-dioxopurines, 2H-1,2,3-triazolyl[4,5-d]pyrimidines, or 1,2,5-thadiazolyl[3,4-d]pyrimidines; antiproliferative, antiinflammatory, and antiarthritic agents; psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, lupus, graft versus host disease | CELL THERAPEUTICS, INC. (US) | 2005-02-10 | — | — | US | disclosed |
| US-6774130-B2 | TREATING CHRONIC INFLAMMATORY DISEASE, CHRONIC INTESTINAL INFLAMMATION, ARTHRITIS, PSORIASIS, ASTHMA AND AUTOIMMUNE DISORDERS; TH1 CELL-MEDIATED DISORDERS; FOR EXAMPLE, 1,2,3,6-TETRAHYDRO-7H-PURINE-2,6-DIONE DERIVATIVES | CELL THERAPEUTICS, INC. | 2004-08-10 | — | — | US | disclosed |
| US-20020028823-A1 | THERAPEUTIC COMPOUNDS FOR INHIBITING INTERLEUKIN-12 SIGNALING AND METHODS FOR USING SAME | CELL THERAPEUTICS, INC. | 2002-03-07 | — | — | US | disclosed |
| EP-1171442-A1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALLING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000061583-A1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032748-A1 | Substituted 2,5-dioxopurines, 2H-1,2,3-triazolyl[4,5-d]pyrimidines, or 1,2,5-thadiazolyl[3,4-d]pyrimidines; antiproliferative, antiinflammatory, and antiarthritic agents; psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, lupus, graft versus host disease | TPMT, IL2, NFATC1 | ALDH1A1 799/4885KDM4E 3980/4885KMT2A 3473/4885 |
| US-20020028823-A1 | THERAPEUTIC COMPOUNDS FOR INHIBITING INTERLEUKIN-12 SIGNALING AND METHODS FOR USING SAME | CCR10, IL1RN, CCR1 | ALDH1A1 919/4885KDM4E 4479/4885KMT2A 4716/4885 |
| US-20050049262-A1 | Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same | IL2, CCR10, CCR1 | ALDH1A1 1906/4885KDM4E 4301/4885KMT2A 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.